Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Biophytis (BPTS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Biophytis's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Please note: Biophytis performed a 1:40 stock split on Apr 23, 2024
9.8200 -1.7840    -15.37%
22/04 - Closed. Currency in USD ( Disclaimer )
After Hours
0.2400
-0.0055
-2.2403%
18:57:30 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 8,835
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 8.9680 - 11.2000
Biophytis 9.8200 -1.7840 -15.37%

Biophytis Company Profile

 
Get an in-depth profile of Biophytis, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

24

Equity Type

ORD

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company’s lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Contact Information

Address Sorbonne University BC 9, BAtiment A 4Eme Etage
4 place Jussieu Cedex 05 Paris, 75005
France
Phone 33 1 44 27 23 00
Fax -

Top Executives

Name Age Since Title
Nadine Coulm 58 2015 Independent Director
Stanislas Veillet 56 2015 Chairman of the Board & CEO
Rene Lafont 76 2011 Scientific Advisor & Member of Scientific Advisory Board
Thomas Voit - 2017 Member of Scientific Advisory Board
Jose-Alain Sahel - - Member of Scientific Advisory Board
Jean Mariani 74 2016 Chairman of Scientific Advisory Board & Director
Roger A. Fielding - 2016 Member of Scientific Advisory Board
Yann Meunier - 2023 Member of Scientific Advisory Board
Claude Allary 68 2021 Independent Director
Bernard Levy - 2023 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BPTS Comments

Write your thoughts about Biophytis
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Aliyu Iliyasu Ahmad
Aliyu Iliyasu Ahmad Mar 23, 2022 5:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm a new hire
Nacho Luque
Nacho Luque Feb 19, 2021 11:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So nice!! C´mon
Javier Abascal
Javier Abascal Feb 16, 2021 10:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Let's go!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email